Adrenal Carcinoma, Adrenal Nodule/Mass, Pituitary Macroadenoma, Pituitary Microadenoma, Pituitary Neoplasm, Thyroid Cancer, Thyroid Nodule/Mass
Dr. Sarimar Agosto Salgado is an Assistant Member in the Department of Head and Neck-Endocrine Oncology. Dr. Agosto Salgado received her medical degree from the University of Puerto Rico School of Medicine. After completion of Internal Medicine Residency in Puerto Rico, she specialized in Endocrinology, Diabetes and Metabolism Fellowship at the University of Texas Health Science Center at San Antonio, Texas. Dr. Agosto Salgado subspecialized in Endocrine Oncology by completing the Oncologic Endocrinology Fellowship at the University of Texas MD Anderson Cancer Center in Houston, Texas. She joins us from UT Southwestern Medical Center, Division of Endocrinology. Dr. Agosto Salgado‘s clinical interest centers on the management of thyroid nodules and all stages and types of thyroid cancer, including administration of systemic therapies for aggressive tumors. She is also interested in the management of hereditary endocrine neoplasia disorders, pituitary tumors, adrenal tumors, adrenocortical carcinoma and pheochromocytoma-paraganglioma tumors. Her research interest focuses on intermediate-high risk thyroid cancers in terms of management, surveillance protocols, targeted therapies and potential redifferentiation of tumors resistant to radioactive iodine. Dr. Agosto is fluent in English & Spanish.
Education & Training
- MD Anderson Cancer Center - Oncologic Endocrinology
- University of Texas Health Sciences Center - Endocrinology, Diabetes & Metabolism
- University of Puerto Rico, Medical Sciences Campus School of Medicine - MD
- Agosto Salgado S, Kaye ER, Sargi Z, Chung CH, Papaleontiou M. Management of Advanced Thyroid Cancer: Overview, Advances, and Opportunities. Am Soc Clin Oncol Educ Book. 2023 May.43:e389708. Pubmedid: 37186883.
- Agosto Salgado S. Evolution of anaplastic thyroid cancer management: perspectives in the era of precision oncology. Ther Adv Endocrinol Metab. 2021 Oct.12. Pubmedid: 34733469. Pmcid: PMC8558801.
- Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2021 Jul.19(7):839-868. Pubmedid: 34340212.
- Armaiz-Pena G, Flores SK, Cheng ZM, Zhang X, Esquivel E, Poullard N, Vaidyanathan A, Liu Q, Michalek J, Santillan-Gomez AA, Liss M, Ahmadi S, Katselnik D, Maldonado E, Salgado SA, Jimenez C, Fishbein L, Hamidi O, Else T, Lechan R, Tischler AS, Benn DE, Dwight T, Clifton-Bligh R, Sanso G, Barontini M, Vincent D, Aronin N, Biondi B, Koops M, Bowhay-Carnes E, Gimenez-Roqueplo AP, Alvarez-Eslava A, Bruder JM, Kitano M, Burnichon N, Ding Y, Dahia PLM. Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. J Clin Endocrinol Metab. 2021 Jan.106(1):e350-e364. Pubmedid: 33051659. Pmcid: PMC7765648.
- Toro-Tobón D, Agosto S, Ahmadi S, Koops M, Bruder JM. Chronic Myeloid Leukemia Associated Hypercalcemia: A Case Report and Literature Review. Am J Case Rep. 2017 Feb.18:203-207. Pubmedid: 28239141. Pmcid: PMC5340222.
Patient CommentsOverall Satisfaction4.8
195 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.Learn more about our patient satisfaction survey
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.